Let's Talk About Your Breasts
Let's Talk About Your Breasts
Dorothy Gibbons, CEO & Cofounder
Early Screening, Genetic Testing, and Hope After Loss to Metastatic Breast Cancer
35 minutes Posted Apr 21, 2026 at 5:00 am.
Board recruitment and early connection to The Rose02:30 High risk programs, navigation, and genetic testing03:45 Mother’s de novo metastatic diagnosis and treatment in the 1990s08:30 Limited options then versus today’s targeted therapies10:00 Role of subtyping, genetics, and clinical trials now11:30 How trials work, ongoing treatment, and progression13:00 Starting early mammograms and self advocacy in her 30s17:30 Younger women, “too young” barriers, and trusting your body21:30 Advanced breast cancer steering committee and research funding24:30 Boot Walk fundraising and metastatic specific projects28:00 Broader volunteer work and intensity of patient needs31:00 Navigation, uninsured women, and final call to advocateSee omnystudio.com/listener for privacy information.
0:00
35:23
Download MP3
Show notes
After losing her mother to de novo metastatic breast cancer, Elise turned grief into long term advocacy and board service at The Rose. She demystifies modern metastatic care, clinical trials, and lifelong treatment while urging women of every age to push for screenings and answers. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. 10 Key Questions Answered 1. How Elise became involved with The Rose board and metastatic breast cancer advocacy. 2. What happened during her mother’s initial breast cancer diagnosis and why it was classified as de novo metastatic. 3. How metastatic breast cancer treatment looked in the early 1990s, including bone marrow transplant approaches. 4. What key advances have changed metastatic breast cancer care since her mother’s time, such as genetic testing and subtype specific treatments. 5. How clinical trials for metastatic breast cancer usually work today and why they rarely involve placebo without treatment. 6. Why metastatic patients often need lifelong treatment and careful monitoring to stay on effective therapy as long as possible. 7. How advocacy groups and steering committees at MD Anderson direct research funds toward metastatic specific projects. 8. Why self advocacy and persistence with providers can be critical, especially for younger women seeking mammograms or additional testing. 9. How Elise balances her volunteer work, legal background, and family life while staying active on multiple boards and committees. 10. What message she wants women and families to remember about screening, self care, and not putting their own health last. Timestamped Overview 00:00 Board recruitment and early connection to The Rose02:30 High risk programs, navigation, and genetic testing03:45 Mother’s de novo metastatic diagnosis and treatment in the 1990s08:30 Limited options then versus today’s targeted therapies10:00 Role of subtyping, genetics, and clinical trials now11:30 How trials work, ongoing treatment, and progression13:00 Starting early mammograms and self advocacy in her 30s17:30 Younger women, “too young” barriers, and trusting your body21:30 Advanced breast cancer steering committee and research funding24:30 Boot Walk fundraising and metastatic specific projects28:00 Broader volunteer work and intensity of patient needs31:00 Navigation, uninsured women, and final call to advocateSee omnystudio.com/listener for privacy information.